-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $7

Benzinga·05/09/2025 17:51:53
Listen to the news
Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $6 to $7.